Use of a novel mutagenesis strategy, optimized residue substitution, to decrease the off-rate of an anti-gp120 antibody
- PMID: 8544856
- DOI: 10.1016/0161-5890(95)00079-8
Use of a novel mutagenesis strategy, optimized residue substitution, to decrease the off-rate of an anti-gp120 antibody
Abstract
We have developed a novel strategy to decrease the antibody:antigen off-rate which we call optimized residue substitution. This strategy employs alanine substitution to first identify residues non-optimal for binding, as evidenced by a decrease in off-rate upon alanine replacement. These positions are then individually randomized to all amino acids, and the best replacement for each position determined. Finally, a construct which combines all optimized substitutions is generated and evaluated. We applied this strategy to the heavy chain CDR3 of P5Q, a scFv antibody which recognizes an epitope on the V3 loop of HIV gp120. We identified two amino acid substitutions that together decrease the off-rate by nearly ten-fold. The contributions by the two substitutions were near additive, indicative of independent affects on binding. We suggest that this strategy can be generalized to strengthen protein:ligand and protein:protein interactions in other systems.
Similar articles
-
Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.J Mol Biol. 1996 Feb 16;256(1):77-88. doi: 10.1006/jmbi.1996.0069. J Mol Biol. 1996. PMID: 8609615
-
Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig.Int Immunol. 2000 Mar;12(3):305-12. doi: 10.1093/intimm/12.3.305. Int Immunol. 2000. PMID: 10700465
-
CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range.J Mol Biol. 1995 Dec 1;254(3):392-403. doi: 10.1006/jmbi.1995.0626. J Mol Biol. 1995. PMID: 7490758
-
Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody.J Immunol. 2000 Oct 15;165(8):4505-14. doi: 10.4049/jimmunol.165.8.4505. J Immunol. 2000. PMID: 11035090
-
Molecular makeup of HIV-1 envelope protein.Int Rev Immunol. 2004 Sep-Dec;23(5-6):383-411. doi: 10.1080/08830180490432749. Int Rev Immunol. 2004. PMID: 15370272 Review.
Cited by
-
Affinity improvement of the fully human anti‑TSLP recombinant antibody.Mol Med Rep. 2020 Feb;21(2):759-767. doi: 10.3892/mmr.2019.10880. Epub 2019 Dec 12. Mol Med Rep. 2020. PMID: 31974622 Free PMC article.
-
Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.Mol Immunol. 2009 Feb;46(5):917-26. doi: 10.1016/j.molimm.2008.09.005. Epub 2008 Oct 25. Mol Immunol. 2009. PMID: 18952295 Free PMC article.
-
Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.Structure. 2009 Nov 11;17(11):1538-46. doi: 10.1016/j.str.2009.09.012. Structure. 2009. PMID: 19913488 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous